Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiluoming Zhengqing Fengtongning Tablets is an anti-rheumatic traditional Chinese medicine (TCM) formulation developed and manufactured by Hunan Zhengqing Pharmaceutical (also referred to as Hunan Zhongqi Pharmaceutical). The active ingredient is sinomenine hydrochloride, a monomeric alkaloid extracted from the root and stem of *Sinomenium acutum*. It is approved in China for the treatment of rheumatic diseases, including rheumatoid arthritis and osteoarthritis, presenting with wind-cold-dampness arthralgia syndrome (characterized by muscle soreness, joint swelling, pain, and stiffness). Sinomenine hydrochloride exerts anti-inflammatory, analgesic, and immunomodulatory effects, primarily by acting as an agonist of the mu-type opioid receptor and downregulating the NF-κB signaling pathway, which subsequently reduces the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiluoming Zhengqing Fengtongning Tablets.